Daily Endocrinology Research Analysis
Analyzed 29 papers and selected 3 impactful papers.
Summary
A nationwide nested case-control study links clinically established type 1 diabetes to increased Parkinson's disease risk, challenging genetic predictions. A systematic review shows moderate agreement between molecular imaging and adrenal vein sampling for primary aldosteronism localization, supporting complementary diagnostic roles. A decade-long Chinese cohort details worsening obesity and metabolic phenotypes, highlighting modifiable transitions in midlife.
Research Themes
- Endocrine–neurology epidemiology links
- Diagnostic innovation in endocrine hypertension
- Population metabolic health trajectories and risk transitions
Selected Articles
1. Type 1 diabetes and risk of Parkinson's disease: A nationwide nested case-control study.
Using nationwide Korean claims data (2010–2022), clinically established type 1 diabetes was associated with a higher risk of Parkinson's disease (adjusted OR 1.42). The association persisted irrespective of microvascular complications, contrasting prior genetic liability findings.
Impact: This large-scale, real-world analysis challenges Mendelian randomization results and highlights potential non-genetic mechanisms linking T1D to neurodegeneration.
Clinical Implications: Clinicians should maintain vigilance for prodromal Parkinsonian features in long-term T1D care and consider integrating targeted neurologic screening and counseling while research clarifies mechanisms.
Key Findings
- Clinically established T1DM independently increased PD risk (aOR 1.42, 95% CI 1.06–1.90).
- The association was consistent regardless of microvascular complications.
- Findings contrast with Mendelian randomization suggesting protective genetic liability, implying non-genetic pathways.
Methodological Strengths
- Nationwide, population-based nested case-control design with age/sex matching
- Adjusted for vascular and metabolic comorbidities using conditional logistic regression
Limitations
- Reliance on administrative claims may introduce misclassification
- Lifestyle and environmental confounders were not captured; causality cannot be established
Future Directions: Prospective cohorts with detailed phenotyping and mechanistic studies (e.g., inflammation, glycemic variability, insulin exposure) to elucidate pathways linking T1D to PD.
BACKGROUND: Recent Mendelian randomization studies have suggested a protective association of genetic liability to Type 1 diabetes mellitus (T1DM) with Parkinson's disease (PD). OBJECTIVE: To investigate the association between clinically established T1DM and PD risk in a nationwide population-based cohort. METHODS: We conducted a nested case-control study using data from the Korean National Health Insurance Service (NHIS) database (2010-2022). Patients with incident PD were matched with controls by age and sex. Conditional logistic regression was used to estimate adjusted odds ratios (aORs), controlling for vascular and metabolic comorbidities. RESULTS: T1DM was independently associated with an increased PD risk (aOR 1.42, 95% CI 1.06-1.90). The association was directionally consistent regardless of the presence of microvascular complication. CONCLUSION: In contrast to genetic studies, clinically established T1DM was associated with greater PD risk. These findings suggest that clinically established T1DM may be associated with increased PD risk through mechanisms beyond immunogenetic susceptibility, although the underlying pathways remain to be clarified.
2. Agreement Between Molecular Imaging and Adrenal Vein Sampling for Localization in Primary Aldosteronism: A Systematic Review.
Across 20 studies, molecular imaging demonstrated moderate agreement with AVS for lateralization in primary aldosteronism (positive agreement 0.6–0.9; negative 0.5–0.9; κ 0.33–0.93). Heterogeneity across tracers precluded pooling, supporting tracer-specific, complementary use within diagnostic algorithms.
Impact: Clarifies the real-world concordance between a noninvasive modality and the invasive gold standard in a surgically curable endocrine hypertension, informing patient selection and pathways.
Clinical Implications: Molecular imaging can be considered as an adjunct or alternative to AVS when AVS is unavailable, contraindicated, or inconclusive, with tracer-specific protocols and multidisciplinary evaluation.
Key Findings
- Moderate agreement between molecular imaging and AVS: positive percent agreement 0.6–0.9; negative 0.5–0.9.
- Cohen’s κ ranged 0.33–0.93, indicating moderate-to-strong agreement beyond chance.
- Heterogeneity across tracers and protocols precluded quantitative pooling and direct tracer comparisons.
- Reciprocal analyses showed no consistent directional bias, supporting complementary roles.
Methodological Strengths
- Head-to-head comparisons against prespecified AVS localization criteria
- Use of multiple agreement metrics (positive/negative agreement, Cohen’s κ) and tracer-stratified analyses
Limitations
- Heterogeneity in tracer protocols, patient preparation, and interpretation prevented meta-analysis
- Lack of patient outcome-based studies linking localization strategy to surgical cure and long-term outcomes
Future Directions: Prospective, outcome-linked studies comparing diagnostic pathways (AVS vs molecular imaging or combined) to quantify impact on surgical eligibility, cure rates, and cost-effectiveness.
BACKGROUND: Primary aldosteronism is a common cause of hypertension that is curable via surgery when localized to a single adrenal gland. Localization testing has traditionally relied upon adrenal vein sampling (AVS); however, molecular imaging has emerged as a promising noninvasive alternative. METHODS: We performed a systematic synthesis of studies comparing molecular imaging with AVS for localization in primary aldosteronism. Studies directly comparing both modalities with prespecified AVS localization criteria were eligible. Agreement was evaluated using positive percent agreement, negative percent agreement, and, where available, Cohen's κ. Because molecular imaging tracers differ in biological targets and interpretation criteria, agreement metrics were examined by tracer rather than pooled. Sensitivity analyses repeated positive percent agreement and negative percent agreement calculations using molecular imaging as the reference. RESULTS: Twenty studies were included. Across tracers, agreement between molecular imaging and AVS was moderate, with positive percent agreement values ranging from 0.6 to 0.9 and negative percent agreement from 0.5 to 0.9. Cohen's κ values ranged from 0.33 to 0.93, indicating moderate-to-strong agreement beyond chance. Each tracer was assessed separately; direct comparisons between tracers were not performed, and quantitative pooling was not undertaken because of heterogeneity in tracer protocols, patient preparation, and test interpretation. Reciprocal analyses yielded similar positive percent agreement and negative percent agreement distributions, with no consistent directional bias between modalities. CONCLUSIONS: Molecular imaging shows moderate and variable agreement with AVS for localization testing in primary aldosteronism, suggesting complementary rather than competing roles. Molecular imaging may serve as an adjunct or alternative within diagnostic algorithms; however, patient outcome-based studies are still needed to define its clinical utility.
3. Decadal trends in obesity and metabolic health phenotypes among middle-aged and older adults in China (2014-2024): insights from the KARE cohort study.
In the KARE cohort (2014–2024), overall and abdominal obesity increased substantially, with MUO predominating and MHO also rising. Longitudinally, over half shifted BMI categories; overweight often progressed to obesity, whereas reversal from obesity to normal weight was rare, and abdominal obesity persisted, especially in women.
Impact: Provides large-scale, objectively measured, decade-long transitions in obesity and metabolic phenotypes, identifying midlife as a critical prevention window and informing risk stratification.
Clinical Implications: Prioritize midlife interventions to prevent progression from overweight to obesity; in older adults, combine BMI, waist circumference, and metabolic markers to identify high-risk MUO transitions and tailor sex-specific strategies.
Key Findings
- Overall obesity rose from 38.43% to 44.01% over 10 years; abdominal obesity from 42.91% to 54.64%.
- MUO predominated (>50%), while MHO increased from 13.18% to 19.10%.
- Longitudinally, 52.34% changed BMI category; 38.32% of overweight progressed to obesity, only 4.80% of obesity returned to normal weight.
- Abdominal obesity persisted, especially in women (59.46% maintained).
- 48% of MHO transitioned to MUO; 20% of MONW regained metabolic health.
Methodological Strengths
- Very large sample with professionally measured anthropometrics
- Combined repeated cross-sectional and longitudinal transition analyses
Limitations
- Single-region cohort may limit generalizability across China
- Observational design with potential residual confounding
Future Directions: Evaluate targeted, midlife prevention strategies and sex-specific interventions; integrate wearable/EHR data to personalize risk trajectories and test reversal of abdominal obesity.
BACKGROUND AND AIM: China faces dual challenges of ageing and obesity, yet long-term cohort evidence on obesity trajectories in midlife and older adulthood remains limited. METHODS AND RESULTS: Utilizing the Kunshan Ageing Research with E-health cohort, we analyzed 2014-2024 obesity trends using professionally measured anthropometrics (repeated cross-sections, n = 69,880-118,639) and individual transition patterns (longitudinal analysis, n = 40,335-42,601). Over ten years, overall obesity prevalence among middle-aged/older adults rose significantly from 38.43% to 44.01%. Abdominal obesity surged from 42.91% to 54.64%. Metabolically unhealthy overweight/obesity (MUO) consistently predominated (>50%), yet metabolically healthy overweight/obesity (MHO) prevalence also increased markedly (13.18% to 19.10%). Longitudinally, 52.34% changed BMI category. Individuals with overweight progressed to obesity at 38.32%, while only 4.80% of those with obesity achieved normal weight. Abdominal obesity proved persistent, especially in women (59.46% maintained). Metabolically, 48.00% of MHO transitioned to MUO; 20.00% of metabolically unhealthy normal weight (MONW) individuals regained metabolic health. CONCLUSIONS: Obesity burden has risen markedly, with faster increases in men and high rates in older women. Because overweight appeared more modifiable than established obesity, midlife may be a key period for prevention, while combined monitoring of BMI, waist circumference, and metabolic markers in older adults may help identify high-risk individuals.